
TY  - JOUR
TI  - Abstracts
JO  - Pediatric Transplantation
VL  - 15
IS  - s1
SN  - 1397-3142
UR  - https://doi.org/10.1111/j.1399-3046.2011.01525.x
DO  - doi:10.1111/j.1399-3046.2011.01525.x
SP  - 41
EP  - 139
PY  - 2011
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - Transplant International
VL  - 24
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2011.01346.x
DO  - doi:10.1111/j.1432-2277.2011.01346.x
SP  - 1
EP  - 95
PY  - 2011
ER  - 

TY  - JOUR
AU  - Schmidt, D. E.
AU  - Majeed, A.
AU  - Bruzelius, M.
AU  - Odeberg, J.
AU  - Holmström, M.
AU  - Ågren, A.
TI  - A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease
JO  - Haemophilia
JA  - Haemophilia
VL  - 23
IS  - 2
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.13121
DO  - doi:10.1111/hae.13121
SP  - 309
EP  - 318
KW  - diagnosis
KW  - monitoring
KW  - ROTEM
KW  - thromboelastography
KW  - von Willebrand disease
PY  - 2017
AB  - Introduction Rotational thromboelastometry (ROTEM?) and thromboelastography (TEG?) are increasingly used in the perioperative and emergency assessment of bleeding tendencies. The diagnostic value of ROTEM and TEG for von Willebrand disease (VWD) remains to be established. Aim To investigate whether ROTEM and TEG can discriminate patients with VWD from healthy controls. Methods Rotational thromboelastometry and TEG whole blood coagulation profiles were compared between VWD patients (n = 100) and healthy controls (n = 89). Measures of diagnostic accuracy were calculated, including sensitivity, specificity and receiver operating characteristic (ROC) curve. Results Prolonged TEG R-time had a positive and negative predictive value (PPV, NPV) of 0.84 and 0.68 respectively. TEG clotting index (CI) had a PPV of 1.00 and an NPV of 0.60. Both R-time and CI had a high specificity and accurately discriminated VWD patients from healthy controls, with an ROC area under the curve of 0.85 and 0.99 respectively. In multivariate analysis, low FVIII levels, but not von Willebrand factor (VWF) antigen or activity, determined hypocoagulable TEG R (R2 = 0.35) and CI levels (R2 = 0.51). The ROTEM coagulation profiles of VWD patients did not differ from healthy controls. Conclusions Thromboelastography R and CI accurately discriminated VWD patients from healthy controls, partly through the detection of low FVIII levels. The test's performance may be improved through adjustment of the test thresholds to a local reference population. Both intrinsic pathway-activated (INTEM) and tissue factor pathway-activated (EXTEM) ROTEM were of limited diagnostic value in VWD.
ER  - 

TY  - JOUR
AU  - Buvat, J.
AU  - Waldkirch, E.
TI  - P-01 Hormones and Sexuality
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_1.x
DO  - doi:10.1111/j.1743-6109.2007.00390_1.x
SP  - 105
EP  - 108
PY  - 2007
ER  - 

TY  - JOUR
AU  - Corona, G.
AU  - Simonsen, U.
TI  - MP-03 Physiology and Pathophysiology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_10.x
DO  - doi:10.1111/j.1743-6109.2007.00390_10.x
SP  - 138
EP  - 143
PY  - 2007
ER  - 

TY  - JOUR
TI  - PP-01 Pharmacology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_13.x
DO  - doi:10.1111/j.1743-6109.2007.00390_13.x
SP  - 152
EP  - 161
PY  - 2007
ER  - 

TY  - JOUR
TI  - PP-04 Ejaculatory Disorders
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_16.x
DO  - doi:10.1111/j.1743-6109.2007.00390_16.x
SP  - 183
EP  - 185
PY  - 2007
ER  - 

TY  - JOUR
AU  - Droupy, S.
AU  - Austoni, E.
TI  - P-07 Surgery and Peyronie's Disease
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_7.x
DO  - doi:10.1111/j.1743-6109.2007.00390_7.x
SP  - 124
EP  - 127
PY  - 2007
ER  - 

TY  - JOUR
AU  - Goldstein, I.
AU  - Richardson, D.
TI  - MP-01 Female Sexual Health
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_8.x
DO  - doi:10.1111/j.1743-6109.2007.00390_8.x
SP  - 128
EP  - 132
PY  - 2007
ER  - 

TY  - JOUR
TI  - PP-02 Risk Factors, Hormones and Epidemiology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_14.x
DO  - doi:10.1111/j.1743-6109.2007.00390_14.x
SP  - 162
EP  - 174
PY  - 2007
ER  - 

TY  - JOUR
AU  - Vardi, Y.
AU  - Pedersen, C. Damsted
TI  - P-03 Female Sexual Health
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_3.x
DO  - doi:10.1111/j.1743-6109.2007.00390_3.x
SP  - 111
EP  - 114
PY  - 2007
ER  - 

TY  - JOUR
AU  - Marberger, M.
AU  - Briganti, A.
TI  - P-06 Erectile Dysfunction following Radical Prostatectomy
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_6.x
DO  - doi:10.1111/j.1743-6109.2007.00390_6.x
SP  - 121
EP  - 124
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster Session I (PI 1–89)
JO  - Clinical Pharmacology & Therapeutics
JA  - Clinical Pharmacology & Therapeutics
VL  - 85
IS  - S1
SN  - 0009-9236
UR  - https://doi.org/10.1038/sj.clpt.2008.283
DO  - doi:10.1038/sj.clpt.2008.283
SP  - S9
EP  - S36
PY  - 2009
AB  - Clinical Pharmacology & Therapeutics (2009) 85, S9?S35. doi:10.1038/sj.clpt.2008.36
ER  - 

TY  - JOUR
TI  - THSNA 2018 Summit Abstract Proceedings
JO  - American Journal of Hematology
JA  - Am J Hematol
VL  - 93
IS  - 9
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.25268
DO  - doi:10.1002/ajh.25268
SP  - E253
EP  - E328
PY  - 2018
ER  - 

TY  - JOUR
TI  - MODERATED POSTER SESSION ABSTRACTS
JO  - The Journal of Sexual Medicine
VL  - 3
IS  - s3
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2006.00188_3.x
DO  - doi:10.1111/j.1743-6109.2006.00188_3.x
SP  - 199
EP  - 223
PY  - 2006
ER  - 

TY  - JOUR
TI  - PODIUM SESSION ABSTRACTS
JO  - The Journal of Sexual Medicine
VL  - 3
IS  - s3
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2006.00188_2.x
DO  - doi:10.1111/j.1743-6109.2006.00188_2.x
SP  - 176
EP  - 198
PY  - 2006
ER  - 

TY  - JOUR
TI  - 142nd Annual Meeting of the American Neurological Association
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 82
IS  - S21
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.25024
DO  - doi:10.1002/ana.25024
SP  - S1
EP  - S233
PY  - 2017
ER  - 

TY  - JOUR
AU  - Akkus, E.
AU  - Hatzimouratidis, K.
TI  - MP-02 Pharmacology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_9.x
DO  - doi:10.1111/j.1743-6109.2007.00390_9.x
SP  - 133
EP  - 137
PY  - 2007
ER  - 

TY  - JOUR
TI  - SIOP 2015 Scientific Programme + Index
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 62
IS  - S4
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.25715
DO  - doi:10.1002/pbc.25715
SP  - S143
EP  - S418
PY  - 2015
ER  - 

TY  - JOUR
AU  - Jansen, Christian
AU  - Chatterjee, Devnandan Amor
AU  - Thomsen, Karen Louise
AU  - Al-Kassou, Baravan
AU  - Sawhney, Rohit
AU  - Jones, Helen
AU  - Gallego-Leon, Angela
AU  - Lehmann, Jennifer
AU  - Pohlmann, Alessandra
AU  - Nickenig, Georg
AU  - Strassburg, Christian P.
AU  - Andrié, René
AU  - Jalan, Rajiv
AU  - Linhart, Markus
AU  - Trebicka, Jonel
AU  - Mookerjee, Rajeshwar P.
TI  - Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality
JO  - Alimentary Pharmacology & Therapeutics
JA  - Aliment Pharmacol Ther
VL  - 50
IS  - 5
SN  - 0269-2813
UR  - https://doi.org/10.1111/apt.15365
DO  - doi:10.1111/apt.15365
SP  - 568
EP  - 579
PY  - 2019
AB  - Summary Background Heart rate variability (HRV) is reduced in cirrhosis and in conditions of systemic inflammation. Whether HRV is associated with cirrhosis decompensation and development of acute-on-chronic liver failure (ACLF) is unknown. Aims To (a) validate wireless remote HRV monitoring in cirrhosis decompensation; (b) determine if severely reduced HRV is a surrogate for inflammation and progression of cirrhosis decompensation; (c) assess if measuring HRV determines prognosis in cirrhosis decompensation. Methods One hundred and eleven patients at risk of cirrhosis decompensation at two clinical sites were monitored for HRV. Standard deviation of all normal beat-beat intervals (SDNN) reflecting HRV was assessed using remote monitoring (Isansys Lifetouch) and/or Holter ECG recording. Clinical outcomes and major prognostic scores were recorded during 90-day follow-up. Results Reduced HRV denoted by lower baseline SDNN, correlated with severity of decompensation (median 14 (IQR 11-23) vs 33 (25-42); P < 0.001, decompensated patients vs stable outpatient cirrhosis). Furthermore, SDNN was significantly lower in patients developing ACLF compared to those with only decompensation (median 10 (IQR9-12) vs 16 (11-24); P = 0.02), and correlated inversely with MELD and Child-Pugh scores, and C-reactive protein (all P < 0.0001) and white cell count (P < 0.001). SDNN predicted disease progression on repeat measures and appeared an independent predictor of 90-day mortality (12 patients). An SDNN cut-off of 13.25 ms had a 98% negative predictive value. Conclusions This study demonstrates that remote wireless HRV monitoring identifies cirrhosis patients at high risk of developing ACLF and death, and suggests such monitoring might guide the need for early intervention in such patients. Clinical Trial number: NIHR clinical research network CPMS ID 4949.
ER  - 
